

1 Medicated Janus fibers fabricated using a  
2 Teflon-coated side-by-side spinneret

3 Deng-Guang Yu <sup>a,\*</sup>, Ying Xu <sup>a</sup>, Miao Jin <sup>b</sup>, Gareth R. Williams <sup>b</sup>, Hua Zou <sup>a</sup>,  
4 Xia Wang <sup>a,\*</sup>, S.W. Annie Bligh <sup>c,\*</sup>

5  
6  
7 <sup>a</sup> School of Materials Science & Engineering, University of Shanghai for Science and  
8 Technology, Shanghai 200093, China.

9 <sup>b</sup> UCL School of Pharmacy, University College London, London WC1N 1AX, UK.

10 <sup>c</sup> Faculty of Science and Technology, University of Westminster, 115 New Cavendish  
11 Street, London W1W 6UW, UK.

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29 **\* Corresponding authors:**

30 Prof. Deng-Guang, Prof. SW Annie Bligh and Prof. Xia Wang

31  
32 **Address:**

33 School of Materials Science & Engineering,  
34 University of Shanghai for Science and Technology,  
35 516 Jungong Road, Yangpu District,  
36 Shanghai 200093, P.R. China

37 **Tel:** +86-21-55270632

38 **Fax:** +86-21-55270632

39 **Email:** ydg017@usst.edu.cn; a.bligh@westminster.ac.uk; wangxia@usst.edu.cn  
40  
41  
42

43 **ABSTRACT:**

44 A ~~few~~ family of medicated Janus fibers that provides a highly tunable biphasic drug  
45 release ~~were~~ was fabricated using a side-by-side electrospinning process employing a  
46 Teflon-coated parallel spinneret. The coated spinneret facilitated the formation of a  
47 Janus Taylor cone and in turn high quality integrated Janus structures, which could not  
48 be reliably obtained without the Teflon coating. The fibers prepared had one side  
49 consisting of polyvinylpyrrolidone (PVP) K60 and ketoprofen, and the other of ethyl  
50 cellulose (EC) and ketoprofen. To modulate and tune drug release, PVP K10 was  
51 doped into the EC side in some cases. The fibers were linear and had flat  
52 morphologies with an indent in the center. They provide biphasic drug release, with  
53 the PVP K60 side dissolving very rapidly to deliver a loading dose of the active  
54 ingredient, and the EC side resulting in sustained release of the remaining ketoprofen.  
55 The addition of PVP K10 to the EC side was able to accelerate the second stage of  
56 release; variation in the dopant amount permitted the release rate and extent ~~in the~~  
57 ~~second, sustained, phase~~ this phase to be precisely tuned. These results offer the  
58 potential to rationally design systems with highly controllable drug release profiles,  
59 which can complement natural biological rhythms and deliver maximum therapeutic  
60 effects.

61 **KEYWORDS:** Janus fibers; side-by-side electrospinning; Teflon-coated spinneret;  
62 nano drug delivery systems; tunable release rates; structural nanocomposites

63

64

65

## 66 **1. Introduction**

67 A range of “top-down” nanofabrication techniques exists, but of these  
68 electrohydrodynamic atomization (EHDA, including electrospinning, electrospraying  
69 and e-jet printing) is particularly attractive because of its simplicity and capability to  
70 propagate the structure of a macroscale template into a nanostructure [1,2]. An EHDA  
71 process typically involves preparing a solution of a polymer (possibly also with a  
72 functional component) in a volatile solvent. This solution is then ejected at a precisely  
73 controlled rate from a syringe fitted with a metal needle (spinneret) towards a  
74 grounded collector plate [3-7]. A large potential difference is applied between the  
75 spinneret and collector plate. This electrical energy causes very rapid evaporation of  
76 the solvent, leading to a solid product. The spatial distribution of components in the  
77 latter mirrors that in the spinneret.

78 Considering a two-compartment system, the simplest structures are i) core-shell  
79 (with different interior and exterior) and ii) an asymmetric Janus structure, where the  
80 sides of the structure are different. Both can be used to develop materials with tunable  
81 or multifunctional properties. Core-shell structures, including fibers and particles,  
82 generated by EHDA have been widely explored [8,9]. These are most commonly  
83 fabricated from a concentric spinneret [10,11], although they can also be prepared  
84 using a single fluid process [12,13]. More complex structures such as three-layer  
85 nanofibers and microparticles (from tri-axial EHDA processes) and  
86 multi-compartmental structures from multiple fluid spinnerets have also been reported

87 [14,15]. However, there are very few publications reporting electrospun Janus fibers,  
88 although there are hundreds on electrospun core-shell nanofibers.

89 Unlike core/shell architectures the Janus structure permits direct contact of both  
90 compartments with their environment, which can be very useful in the creation of  
91 multi-functional nanoscale products [16]. Such structure types are also commonly  
92 found in nature [17], and Janus nanoparticles *are currently one of the one of the most*  
93 *high profile topics in the nano field* [18,19]. ~~In sharp contrast, very little attention has~~  
94 ~~been paid to Janus fibers.~~ Since Gupta and Wilkes first reported the fabrication of  
95 ~~such~~ Janus fibers using side-by-side electrospinning with polyvinyl  
96 chloride/polyurethane and polyvinyl chloride/polyvinylidene fluoride [20], only a  
97 very limited number of additional studies have followed their initial work [21-23].  
98 This can be attributed to the difficulty of creating integrated Janus nanostructures  
99 when parallel metal capillaries are used as a spinneret for side-by-side  
100 electrospinning.

101 Biphasic controlled release of an active ingredient is much sought after in  
102 pharmaceuticals, particularly with an initial rapid release stage followed by sustained  
103 release. Drug delivery systems (DDS) providing such release profiles can deliver an  
104 effective “loading dose”, producing a rapid rise in the plasma concentration of drug  
105 and rapidly relieving a patient’s symptoms. Subsequently, a prolonged-release phase  
106 maintains an effective therapeutic concentration, avoiding repeated administrations  
107 [24].

108 Different types of biphasic release DDS for potential oral administration have

109 been reported, fabricated using a wide variety of technologies [25]. Biphasic release  
110 fibers from single fluid electrospinning have been generated through the encapsulation  
111 of nanoparticles in the fibers [26] or the collection of different types of fibers in a  
112 layer-by-layer manner [27]. However, the former method involved a complex  
113 multiple-step preparation process, and the layer-by-layer collection of different fibers  
114 often resulted in non-homogeneous products. Coaxial electrospinning can yield  
115 biphasic release DDSs in a single step, as a result of its ability to produce materials  
116 where the composition of the core and shell are different [24,25]. By changing the  
117 shell-to-core fluid flow rate ratio [24] or the concentration of drug in the working fluids  
118 [28], a tunable biphasic release profile with accurate control of the amount of drug  
119 released in the different phases can be realized.

120       However, to date there are no reports describing the tuning of the release rate in  
121 the sustained phase of release in an electrospun biphasic DDS. Being able to precisely  
122 control the rate of sustained release is important to ensure the most effective and safe  
123 pharmacokinetic profile for a particular disease, and to facilitate maximum absorbance  
124 of the drug after oral administration. For many drugs, absorption is moderately slow in  
125 the stomach, rapid in the proximal intestine, and declines sharply in the distal segment  
126 of the intestine [29].

127       In this work, we aimed to develop a new side-by-side electrospinning process for  
128 creating integrated Janus fibers. A new Teflon-coated spinneret was exploited to ensure  
129 the two working fluids converge before they were ejected from the spinneret. A series  
130 of ketoprofen-loaded Janus fibers has been prepared using poly(vinylpyrrolidone)

131 (PVP) K60 and ethyl cellulose (EC). The fibers exhibit biphasic drug release, with an  
132 initial burst release followed by sustained freeing of drug into solution. The release rate  
133 and extent in the second phase can be tuned by doping small amounts of PVP K10 into  
134 the EC side of the fiber systems. As a result, nanoscale drug delivery systems with  
135 highly tunable release profiles have been produced; these cannot easily be achieved  
136 using traditional pharmaceutical technologies, and thus this work offers the potential to  
137 lead to a range of new medicines and concomitant patient benefit.

## 138 **2. Experimental**

### 139 **2.1. Materials**

140 Polyvinylpyrrolidone K60 (PVP K60,  $M_w=360,000$ ) and PVP K10 ( $M_w=10,000$ ) were  
141 purchased from Sigma-Aldrich Ltd. (Shanghai, China). Ethyl cellulose (EC, 6mPa·s to  
142 9 mPa·s) was obtained from the Aladdin Chemistry Co. Ltd. (Shanghai, China).  
143 Ketepfen (KET) was purchased from the Wuhan Fortuna Chemical Co. Ltd. (Hubei,  
144 China). Methylene blue and anhydrous ethanol were obtained from the Sinopharm  
145 Chemical Reagent Co. Ltd. (Shanghai, China). All other chemicals used were  
146 analytical grade. Water was doubly distilled immediately prior to use.

### 147 **2.2. Side-by-side electrospinning**

148 After initial optimization experiments, the solutions used for electrospinning  
149 consisted of (1) 8% (w/v) PVP K60 and 2% (w/v) KET in ethanol, and (2) 24% (w/v)  
150 EC, 2% (w/v) KET and a varied content of PVP K10 (0, 1, 2, and 5% (w/v)) in ethanol.

151 Two homemade side-by-side spinnerets were used for electrospinning. A flat  
152 piece of cardboard covered with aluminum foil was earthed and used as the collector

153 plate. Two syringe pumps (KDS100 and KDS200, Cole-Parmer<sup>®</sup>, Vernon Hills, IL,  
154 USA) were used to drive the working fluids. A ZGF 60kV/2mA power supply  
155 (Shanghai Sute Corp., Shanghai, China) was employed to provide a potential  
156 difference between the spinneret and collector.

157 Electrospinning was conducted under ambient conditions ( $24 \pm 2$  °C with a  
158 relative humidity of  $51 \pm 7$  %). After optimization, the applied voltage was fixed at 12  
159 kV, the fiber to collector distance at 20 cm and the flow rates of both the PVP K60 and  
160 EC solutions set to 1.0 mL/h. The electrospinning processes were recorded using a  
161 digital video recorder (PowerShot A490, Canon, Tokyo, Japan).

## 162 **2.3. Characterization**

### 163 *2.3.1. Morphology and structure*

164 The morphologies of the fiber products were investigated using a Quanta FEG450  
165 field-emission scanning electron microscope (FESEM, FEI Corporation, Hillsboro,  
166 USA). The samples were subjected to gold sputter-coating in a nitrogen atmosphere  
167 prior to imaging. Average sizes (diameters for monolithic nanofibers and widths for  
168 Janus fibers) were determined by measuring the fibers at more than 100 different  
169 places in FESEM images, using the Image J software (National Institutes of Health,  
170 Bethesda, USA).

171 The fiber structures were also studied on a JEM 2100F field-emission  
172 transmission electron microscope (TEM, JEOL, Tokyo, Japan). TEM samples were  
173 prepared by placing a lacey carbon-coated copper grid on the fiber collector and  
174 electrospinning onto it for several minutes.

### 175 2.3.2. Functional performance

176 *In vitro* dissolution tests were conducted according to the Chinese Pharmacopoeia  
177 (2010 ed.) Method II, a paddle method. Experiments were undertaken using a RCZ-8A  
178 dissolution apparatus (Tianjin University Radio Factory, Tianjin, China).

179 A mass of fibers containing 40 mg KET (200, 519, 360, 370, 381 and 408 mg for  
180 fibers F1, F2, F3, F4, F5 and F6, respectively) was placed in 800 mL physiological  
181 saline (PS, 0.9% wt) at  $37 \pm 1$  °C, providing sink conditions with  $C < 0.2C_s$ . The  
182 dissolution vessels were stirred at 50 rpm. At predetermined time points, 5.0 mL  
183 aliquots were withdrawn from the dissolution medium and replaced with fresh PS to  
184 maintain a constant volume. After filtration through a 0.22  $\mu$ m membrane (Millipore,  
185 Billerica, USA) and appropriate dilution with PS, the samples were analyzed at  $\lambda_{\max} =$   
186 260 nm using a UV-vis spectrophotometer (UV-2102PC, Unico Instrument Co. Ltd.,  
187 Shanghai, China). The accumulative KET released was back-calculated from the data  
188 obtained against a predetermined calibration curve. All experiments were repeated six  
189 times, and results given as mean  $\pm$  S.D.

## 190 3. Results and discussion

### 191 3.1. Implementation of the side-by-side electrospinning

192 Traditionally, a side-by-side spinneret comprises two parallel metal capillaries.  
193 Here, we used a section of Teflon tube to coat the parallel metal capillaries on their  
194 outlets and project slightly over their nozzles (see the Supplementary Information, Fig.  
195 S1). The Teflon coating has several advantages: 1) it can effectively prevent the  
196 separation of the two working fluids, which occurs when a traditional parallel



197 spinneret is used; 2) an even distribution of charge around the spinneret is expected to  
 198 be achieved; 3) because Teflon is non-conductive, all the charge from the power  
 199 supply can be directed effectively to the working fluids [25]; 4) the non-stick nature of  
 200 Teflon will mean that fibers should not stick to the spinneret, and thus clogging can be  
 201 avoided. These factors should all facilitate the formation of a Janus Taylor cone [30].

202 **Table 1.** Details of the electrospinning processes and the resultant products.

No.	Process	PVP K60 side <sup>a</sup>		EC side			Size <sup>b</sup> (μm)	<i>P</i> <sup>c</sup> (%)
		Flow rate (mL/h)	Flow rate (mL/h)	Composition (% w/v)				
				EC	KET	PVP K10		
F1	Single	1.0	--	--	--	--	0.57±0.09	20
F2	Single	--	1.0	24	2	0	0.68±0.13	7.7
F3	Side-by-side	1.0	1.0	24	2	0	0.92±0.10	11.1
F4	Side-by-side	1.0	1.0	24	2	1	1.02±0.17	10.8
F5	Side-by-side	1.0	1.0	24	2	2	0.98±0.13	10.5
F6	Side-by-side	1.0	1.0	24	2	5	1.06±0.12	9.8

203

204 <sup>a</sup>This fluid consisted of PVP K60 (8% w/v) and KET (2% w/v)

205 <sup>b</sup>Values are shown as mean ± S.D. For F1 and F2, “size” refers the fiber diameter, and for F3 to F6 to the full  
 206 width of the combined Janus fibers.

207 <sup>c</sup>*P* is the total drug content in the solid fibers calculated according to the flow rate and drug content in the fluids:  $P$   
 208 =  $[(F_p \times C_{pd}) + (F_e \times C_{ed})] / [(F_p \times C_{pa}) + (F_e \times C_{ea})] \times 100\%$ .  $F_p$  and  $F_e$  are the flow rates of the PVP side and EC side,  
 209 respectively;  $C_{pd}$  and  $C_{ed}$  the drug contents in PVP and EC sides; and  $C_{pa}$  and  $C_{ea}$  the total solute content in the PVP  
 210 and EC solutions.

211

212 In this study six different fibers, two monolithic and four Janus, were prepared.

213 Details of the electrospinning processes are given in Table 1. The apparatus deployed

214 for side-by-side electrospinning is shown in Fig. 1a. The Teflon-coated spinneret was

215 mounted on a polypropylene syringe containing a PVP K60 solution. The syringe was

216 then placed vertically above the collector. A second syringe containing an EC solution

217 was connected to the second capillary of the spinneret *via* a flexible silicone tube. For

218 easy observation of the electrospinning processes, 0.001% (w/v) of methylene blue

219 was added to the EC solution.


220 After a series of optimization experiments, a stable electrospinning process was  
221 achieved, as depicted in Fig. 1b. A straight fluid jet was emitted from a Janus Taylor  
222 cone (Fig. 1c), followed by an unstable region of bending and whipping with coils of  
223 increasing size. The resultant fiber mat was light blue, with an even blue hue across  
224 the product. This was attributed to the presence of methylene blue; the homogeneous  
225 color distribution is indicative of an integrated Janus structure.

226 In contrast, when the process was performed without the Teflon coating the fiber  
227 mat had an uneven blue color (Fig. 1d), demonstrating a failure to generate integrated  
228 and homogeneous structures. The two fluids used for electrospinning were observed  
229 to separate from one other immediately upon exiting the spinneret (Fig. 1e). When  
230 two fluids are ejected from the nozzles of a side-by-side spinneret, there is only a very  
231 small contact area between them. Since they originate in different capillaries, both  
232 fluids will be charged prior to coming into contact and thus it is inevitable that they  
233 will repel one another, preventing them from converging to form a Janus Taylor cone;  
234 this is illustrated in Fig. 1f(A). This initial repulsive force,  $F_t$ , leads to two Taylor  
235 cones; it is then followed by further repulsion between the two straight fluid jets ( $F_s$ )  
236 and the two bending and whipping coils ( $F_c$ ). These factors result in the failure to  
237 form integrated Janus structures. When the spinneret was coated with Teflon (Fig.  
238 1f(B)), the two fluids are found to first converge, before forming a compound Taylor  
239 cone and ultimately resulting in integrated Janus structures.

240

241

242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262




263 **Fig. 1.** The side-by-side electrospinning process: (a) The experimental apparatus  
264 (inset: the connection of the side-by-side spinneret with the working fluids and power  
265 supply); (b) a photograph of a typical side-by-side electrospinning process with the  
266 Teflon-coated spinneret; (c) a Janus Taylor cone formed with the Teflon-coated  
267 spinneret; (d) the fiber mat from side-by-side electrospinning with the uncoated  
268 side-by-side spinneret; (e) the separation of fluids when using the uncoated spinneret;  
269 (f) an illustration of the role played by the Teflon coating: A - the separation of fluids  
270 arising from repulsive forces  $F_t$  (between the two Taylor cones),  $F_s$  (between the two  
271 straight fluid jets) and  $F_c$  (between the two coils); and B - the formation of an  
272 integrated Janus Taylor cone with the Teflon coating.

### 273 **3.2. Morphologies and structures of the fabricated Janus nanofibers**

274 First, the monolithic fibers F1 and F2 were prepared by single fluid


275 electrospinning using the traditional side-by-side spinneret with one fluid turned off.  
 276 Both fluids individually were found to have good electrospinnability. FESEM images  
 277 of F1 (PVP K60 and KET) are shown in Fig. 2a. The fibers have a linear morphology  
 278 and smooth surfaces, and an average diameter of  $0.57 \pm 0.09 \mu\text{m}$ . The FESEM images  
 279 of F2 (EC and KET) are depicted in Fig. 2b; again the fibers are smooth and linear,  
 280 possessing an average diameter of  $0.68 \pm 0.13 \mu\text{m}$ .

281 The FESEM images of the Janus fibers F3, F4, F5 and F6 are exhibited in Fig. 2c  
 282 to Fig 2f. All have linear morphologies and smooth surfaces. While the monolithic  
 283 fibers are cylindrical in shape, these fibers have a flat concave topography but are still  
 284 linear and smooth. The two sides of the fibers can clearly be resolved. The fiber  
 285 diameters can be found in Table 1. F4 to F6 contain small amounts of PVP K10 doped  
 286 into the EC side of the fibers, but this is found to have no significant influence on  
 287 their size or morphology.



299 **Fig. 2.** FESEM images of the fibers, together with their size distributions: (a) F1  
 300 (drug-loaded PVP fibers); (b) F2 (drug-loaded EC fibers); and the Janus PVP/EC/KET  
 301 fibers (c) F3; (d) F4; (e) F5; (f) F6.

302 TEM images of F3, F4, F5 and F6 are displayed in Fig. 3a to Fig. 3d. Two  
303 different sides to the fibers can again be discerned, with the larger and slightly darker  
304 side being the EC compartment. In the TEM image of F3 (Fig. 3a), there is a central  
305 region with a lower contrast level, suggesting a concave topography. F4 (Fig. 3b)  
306 shows forks resulting from separation of the two sides of the fiber.



307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319 **Fig. 3.** TEM images of (a) F3; (b) F4; (c) F5; (d) F6.

### 320 **3.3. *In vitro* dissolution tests**

321 All the ~~prepared six types~~ of fibers are polymeric composites with KET  
322 presenting in an amorphous ~~status~~ state due to the the existence of hydrogen bonding  
323 and hydrophobic interactions between the drug and its carrier (see the Supplementary  
324 Information, Figs. S2 to S4). In the *in vitro* dissolution tests, the monolithic PVP  
325 fibers F1 provide a very fast drug release profile, freeing all the loaded drug within  
326 one minute (Fig. 4a and Table 2). This can be attributed to the large surface area and  
327 small diameter of the individual nanofibers, the porous 3D web structures of the fiber  
328 mats, the highly hydrophilic and fast-dissolving nature of PVP, and the amorphous  
329 state of KET in the fibers. In contrast, the F2 (EC) fibers give a sustained release

330 profile (Fig. 4a and Table 2), with release of 10.7% and 33.4% in the first minute and  
331 first hour, respectively. After 24 h, 82.5% of the embedded KET has been released.  
332 The Janus fibers F3 to F6 result in biphasic drug release profiles, with ~~part~~ a portion  
333 of the embedded drug being released rapidly into the dissolution medium with the  
334 dissolution of the PVP side of the fibers. Subsequently, the EC side of the fibers leads  
335 to sustained release of KET (Fig. 4a and Table 2). The addition of small amounts of  
336 PVP K10 to the EC side of the fibers permits the release in the second, sustained,  
337 phase to be tuned. An increase in PVP K10 content causes the release rate and the  
338 percentage released after 24h to increase correspondingly (Fig. 4b and Table 2). The  
339 F6 fibers, with 16.1% w/w PVP K10 in the EC side, released all the incorporated drug  
340 within 16 h.

341 The second phase of the *in vitro* dissolution data (up to 16 h) was analyzed using  
342 the zero-order equation and Peppas equations:

343 Zero-order equation [31]:  $Q_z = a + r t_z$

344 (where  $Q_z$  is the release percentage,  $t_z$  is the time,  $a$  is a constant and  $r$  is the release  
345 rate).


346 Peppas equation:  $Q_p = k t_p^n$

347 (where  $Q_p$  is the release percentage,  $t_p$  is the time,  $k$  is a constant and  $n$  is an exponent  
348 that indicates the release mechanism).

349 The results of this analysis are shown in Table 2. Release from the EC side of the  
350 fibers appears to follow a typical Fickian diffusion mechanism; the values of the  
351 exponent  $n$  are all smaller than 0.45. The zero-order equation provides a simple way

352 to compare the release rate ( $r$ ) from the EC side of the different Janus fibers. As the  
 353 content of PVP K10 ( $C$ ) in the EC side was increased from 0% to 3.7%, 7.1% and  
 354 16.1% w/w, the  $r$  values increased correspondingly from 2.16, to 2.31, 2.38 and 2.65  
 355  $h^{-1}$ , respectively. A linear relationship can be established:  $r = 2.1756 + 0.0297C$   
 356 ( $R=0.9964$ ; Fig. 4b). This demonstrates that the drug release rate from the EC matrix  
 357 can be easily manipulated through doping with hydrophilic PVP K10.

358  
 359  
 360  
 361  
 362  
 363  
 364  
 365  
 366  
 367



368 **Fig. 4.** The release of KET from the electrospun nanofibers: (a) the *in vitro* KET  
 369 release profiles from the six fibers; (b) the variation of the release percentage and rate  
 370 in the second phase as a function of the PVP K10 content in the EC side of the fibers.

371  
 372  
 373

**Table 2.** Data on the release of KET from the drug-loaded fibers <sup>a,b</sup> (n=6).

Fiber	First phase (1 min, %)	Rel after 24 h (%)	Second phase of release		
			Rel <sup>c</sup> (%)	Regressed equation (to 16h)	
				Peppas	Zero-order
F1	100±2.8	--	--	--	--
F2	10.7±2.2	82.5±5.3	--	$Q_{p2}=33.46t_{p2}^{0.3252}$ ( $R_{p2}=0.9982$ )	--
F3	50.4±3.9	91.5±4.7	41.1 (41.5)	$Q_{p3}=54.61t_{p3}^{0.1576}$ ( $R_{p3}=0.9921$ )	$Q_{z3}=54.62+2.16t_{z3}$ ( $R_{z3}=0.9773$ )
F4	51.4±4.4	94.7±5.1	43.3 (44.7)	$Q_{p4}=55.54t_{p4}^{0.1621}$ ( $R_{p4}=0.9932$ )	$Q_{z4}=55.44+2.31t_{z4}$ ( $R_{z4}=0.9798$ )
F5	52.3±4.7	98.4±4.3	46.1 (48.4)	$Q_{p5}=59.78t_{p5}^{0.1525}$ ( $R_{p5}=0.9899$ )	$Q_{z5}=58.71+2.38t_{z5}$ ( $R_{z5}=0.9710$ )
F6	54.7±5.2	100.2±3.2	45.5	$Q_{p6}=62.53t_{p6}^{0.1624}$	$Q_{z6}=61.61+2.65t_{z6}$

374

375 <sup>a</sup> The burst release in the first minute is defined as the first phase, and the data between the first minute and 16h  
 376 were used to determine the drug release equations.

377 <sup>b</sup> Abbreviations:  $Q_{p2}$ ,  $t_{p2}$ , and  $R_{p2}$  refer to the release percentage, time and correlation coefficient calculated with the  
 378 Peppas equation for F2.  $Q_{z2}$ ,  $t_{z2}$ , and  $R_{z2}$  are the release percentage, time and correlation coefficient determined with  
 379 the zero-order equation for nanofibers F2. Quantities are defined similarly for the other fibers; the numerical  
 380 subscript gives the identity of the fiber sample under consideration.

381 <sup>c</sup> The percentage released in the second phase was calculated by subtracting the percentage of drug released in the  
 382 first stage from the release percentage after 24 h. The values in brackets represent the percentage of the total  
 383 amount of drug release which came from the EC sides (i.e. the drug content released after 24 h minus 50%, the  
 384 amount of drug in the PVP side of the fibres).

### 385 3.4. Drug release mechanism

386 To investigate the drug release mechanism, samples were recovered from the  
 387 dissolution apparatus after 24h and dried in air. The SEM results, shown in Fig. 5a to  
 388 5d, show the morphologies of the EC side of the fibers (the PVP side dissolves  
 389 completely in a few seconds). Although the overall Janus fibers did not appear to be  
 390 affected by the addition of PVP K10 to the EC side, the size of the fibers recovered  
 391 after 24h of dissolution appears to decrease with an increase of PVP K10 content, and  
 392 they have increasingly curved morphologies (see the Supplementary Information, Fig.  
 393 S5). The remnant nanofibers had rough and wrinkled surfaces, displaying holes and  
 394 grooves; larger PVP K10 contents appear to promote more of these features.

395

396

397

398

399


400

401

402

403

404





405 **Fig. 5.** FESEM images of the fibers remaining after 24h of dissolution and the  
406 proposed drug release mechanism. (a) to (d) show the remains of fibers F3 to F6  
407 respectively; (e) is a schematic diagram explaining the mechanism of drug release  
408 from the Janus fibers.

409 A potential mechanism underlying the biphasic release profile is given in Fig. 5e.  
410 After encountering water, the PVP K60 side of the Janus fibers will dissolve very  
411 rapidly and immediately free all the drug it contains. The remaining EC side provides  
412 the sustained release phase. When there is no PVP K10 in the EC side, as the case of  
413 F3, water diffuses into the EC matrix very slowly. KET is a poorly water soluble drug,  
414 and thus the dissolution of KET and its diffusion from the interior of the fibers to the  
415 dissolution medium proceed very slowly. Because EC is totally insoluble in water, it is  
416 inevitable that a certain amount of KET will remain trapped in the fibers and cannot be  
417 released even after 24h.

418 The PVP K10 doped in the EC side of the fibers is highly soluble in water, and  
419 thus will dissolve rapidly on encountering water. As it does so, it will generate holes  
420 and pores in the EC matrix. The presence of increased amounts of PVP K10 will  
421 enhance this effect. The pores formed after dissolution of PVP K10 will facilitate the  
422 diffusion of water to the interior of the EC matrix, and of KET molecules into the  
423 dissolution media. This in turn increases the drug release rate and amount in the second  
424 phase of release. Further increases of PVP K10 content will yield interconnected pores,  
425 further aiding the movement of water into and drug out of the inside of the fibers, as is  
426 the case ~~in~~ for the Janus fibers F6 (Fig. 5d).

427 As a counterpart of the core-shell structure, the Janus structure can be exploited  
428 to develop a wide variety of functional and multi-functional nanomaterials [32]. The  
429 side-by-side electrospinning process reported here is easy to undertake, and our  
430 results should expand the possibilities for exploiting electrospinning to fabricate novel  
431 functional nanocomposites with Janus morphology. There are many possibilities for  
432 the use of such materials in developing new biomedical materials, in addition to the  
433 tunable biphasic release systems reported here. For example, the fibers could be  
434 exploited to develop systems permitting the controlled release of multiple drugs for a  
435 combined therapy, or for new wound dressings with one side providing adhesive and  
436 anti-inflammatory functions and the other providing sustained release of the active  
437 ingredients required for wound healing. By collecting Janus nanofibers in an aligned  
438 [33] or layer-by-layer fashion [34] additional strategies can be conceived for  
439 generating novel structures and building new structure-property-activity relationships.  
440 Furthermore, coaxial electrospinning allows the field of materials which can be  
441 electrospun to be broadened considerably, as often electrospinning can be achieved  
442 with only one of the two working fluids being electrospinnable on its own [35].  
443 Similarly, it might be possible to implement side-by-side electrospinning using one  
444 spinnable and one unspinnable fluid. This possibility is being studied at present. Much  
445 work has been undertaken to explore the scalability of single-fluid electrospinning  
446 [36,37], with very promising results. Hence, the generation of Janus fibers on a large  
447 scale should be eminently possible, and the novel nanoscale DDS which can be  
448 generated using such fibers have the real possibility for clinical translation [38].

#### 449 **4. Conclusion**

450 In summary, here we developed a Teflon-coated spinneret which could be used for  
451 ~~produce~~ highly effective and stable side-by-side electrospinning. The use of a Teflon  
452 coating can effectively prevent the separation of the two working fluids seen when  
453 attempting electrospinning with no coating. A series of medicated Janus fibers was  
454 successfully fabricated; these ~~comprised two~~ had two distinct sides respectively made  
455 of poly(vinylpyrrolidone) (PVP) K60 and ethyl cellulose (EC), loaded with ketoprofen  
456 (KET) as a model active ingredient. PVP K10 was added to the EC side of the fibers in  
457 some cases; to act as a porogen. Electron microscopy ~~SEM and TEM~~ images clearly  
458 demonstrated that integrated Janus fiber structures were produced, in which the KET  
459 was found to be amorphously distributed. *In vitro* dissolution tests demonstrated that  
460 all the Janus fibers were able to provide a biphasic controlled release profile, with an  
461 initial burst followed a slower and sustained release phase. By varying the amount of  
462 PVP K10 doped in the EC side of the fibers, the release rate and total release  
463 percentage can be precisely tuned. Our results proffer a platform for designing novel  
464 drug delivery systems that can provide a tunable release profile designed to  
465 complement natural biological rhythms for maximum therapeutic effects.

#### 466 **Acknowledgments**

467 This work was supported by the National Science Foundation of China (Nos. 51373101  
468 and 51373100), the China NSFC/UK Royal Society cost share international exchanges  
469 scheme (No. 51411130128/IE131748) and the Hujiang Foundation of China (B14006).

#### 470 **References**

- 471 [1] S. Agarwal, A. Greiner, J.H. Wendorff, *Prog. Polym. Sci.* 38 (2013) 963.
- 472 [2] P. Tonglairoum, T. Ngawhirunpat, T. Rojanarata, R. Kaomongkolgit, P.  
473 Opanasopit, *Colloids Surf. B* 126 (2015) 18.
- 474 [3] W. Liu, Z. Wu, Y. Wang, Z. Tang, J. Du, L. Yuan, D. Li, H. Chen, *J. Mater. Chem.*  
475 *B* 2 (2014) 4272.
- 476 [4] Z. Tang, D. Li, X. Liu, Z. Wu, W. Liu, J.L. Brash, H. Chen, *Polym. Chem.* 4  
477 (2013) 1583.
- 478 [5] W. Yang, J. Fu, D. Wang, T. Wang, H. Wang, S. Jin, N. He, *J. Biomed.*  
479 *Nanotechnol.* 6 (2010) 254.
- 480 [6] X. Ji, T. Wang, L. Guo, J. Xiao, Z. Li, L. Zhang, Y. Deng, N. He, *J. Biomed.*  
481 *Nanotechnol.* 9 (2013) 417.
- 482 [7] Z. Aytac, S.Y. Dogan, T. Tekinay, T. Uyar, *Colloids Surf. B* 120 (2014) 125.
- 483 [8] Q. Shi, Q. Fan, W. Ye, J. Hou, S.C. Wong, X. Xu, J. Yin, *Colloids Surf. B* 125  
484 (2015) 28.
- 485 [9] T. Wang, X. Ji, L. Jin, Z. Feng, J. Wu, J. Zheng, H. Wang, Z.W. Xu, L. Guo, N.  
486 He, *ACS Appl. Mater. Interfaces* 5 (2013) 3757.
- 487 [10] X. Ji, W. Yang, T. Wang, C. Mao, L. Guo, J. Xiao, N. He, *J. Biomed.*  
488 *Nanotechnol.* 9 (2013) 1672.
- 489 [11] W. Wang, Z. Li, T. Jiang, Z. Zhao, Y. Li, Z. Wang, C. Wang, *ACS Appl. Mater.*  
490 *Interfaces* 4 (2012) 6080.
- 491 [12] A.V. Bazilevsky, A.L. Yarin, C.M. Megaridis, *Langmuir* 23 (2007) 2311.
- 492 [13] X. Xu, X. Zhuang, X. Chen, X. Wang, L. Yang, X. Jing, *Macromol. Rapid*

- 493 Commun. 27 (2006) 1637.
- 494 [14] D.G. Yu, X. Li, X. Wang, J. Yang, S.W.A. Bligh, G. Williams, ACS Appl. Mater.  
495 Interfaces 7 (2015) 18891.
- 496 [15] Z. Ahmad, H.B. Zhang, U. Farook, M. Edirisinghe, E. Stride, P. Colombo, J. R.  
497 Soc. Interfaces 5 (2008) 1255.
- 498 [16] W. Chen, Z. Ma, X. Pan, Z. Hu, G. Dong, S. Zhou, M. Peng, J. Qiu, J. Am.  
499 Ceram. Soc. 97 (2014) 1944-1951.
- 500 [17] S. Jiang, S. Granick, (Ed.): Janus particle synthesis, self-assembly and  
501 applications (RSC) 2012, p5-p15.
- 502 [18] J. Hu, S. Zhou, Y. Sun, X. Fang, L. Wu, Chem. Soc. Rev. 41 (2012) 4356.
- 503 [19] A. Walther, A. H. E. Müller, Chem. Rev. 113 (2013) 5194.
- 504 [20] P. Gupta, G. L. Wilkes, Polymer 44 (2003) 6353.
- 505 [21] G. Chen, Y. Xu, D.G. Yu, D.F. Zhang, N.P. Chatterton, K.N. White, Chem.  
506 Commun. 51 (2015) 4623.
- 507 [22] J.D. Starr, J.S. Andrew, Chem. Comm. 49 (2013) 4151.
- 508 [23] J.D. Starr, M. A.K. Budi, J.S. Andrew, J. Am. Ceram. Soc. 98 (2015) 12.
- 509 [24] D.G. Yu, X. Wang, X.Y. Li, W. Chian, Y. Li, Y.Z. Liao, Acta Biomater. 9 (2013)  
510 5665.
- 511 [25] D.G. Yu, F. Liu, L. Cui, Z.P. Liu, X. Wang, S.W.A. Bligh, RSC Adv. 3 (2013)  
512 17775.
- 513 [26] B. Song, C. Wu, J. Chang, Acta Biomater. 8 (2012) 1901.
- 514 [27] L.Y. Huang, C. Branford-White, X.X. Shen, D.G. Yu, L.M. Zhu, Int. J. Pharm.

515 436 (2012) 88.

516 [28] W. Qian, D.G. Yu, Y. Li, Y.Z. Liao, X. Wang, L. Wang, *Int. J. Mol. Sci.* 15 (2014)

517 774.

518 [29] P.K. Gupta, J.R. Robinson, Oral Controlled-release delivery. In: A. Kydonieus,

519 (Ed.), *Treatise on controlled drug delivery*. Marcel Dekker, New York, 1992,

520 pp.255-313.

521 [30] C. Li, Z.H. Wang, D.G. Yu. *Colloids Surf. B* 114 (2014) 404.

522 [31] N.A. Peppas, *Pharm Acta Hel* 60 (1985)110.

523 [32] S. Venkataraman, J.L. Hedrick, Z.Y. Ong, C. Yang, P.L. Rachel Ee, P.T.

524 Hammond, Y.Y. Yang. *Adv. Drug Del. Rev.* 63 (2011) 1228.

525 [33] J. Xie, W. Liu, M.R. MacEwan, P.C. Bridgman, Y. Xia, *ACS Nano* 8 (2014)

526 1878.

527 [34] B. Zhou, Y. Li, H. Deng, Y. Hu, B. Li, *Colloids Surf. B* 116 (2014) 432.

528 [35] Y.H. Wu, D.G. Yu, X.Y. Li, A.H. Diao, U.E. Illangakoon, G.R. Williams, *J. Mater.*

529 *Sci.* 50 (2015) 3604.

530 [36] F. Yener, O. Jirsak, *J. Nanomater.* 2012 (2012) 839317.

531 [37] Z.K. Nagy, A. Balogh, B. Démuth, H. Pataki, T. Vigh, B. Szabó, K. Molnár, B.T.

532 Schmidt, P. Horák, G. Marosi, G. Verreck, I. Van Assche, M.E. Brewster, *Int. J.*

533 *Pharm.* 480 (2015) 137.

534 [38] B. Démuth, Z.K. Nagy, A. Balogh, T. Vigh, G. Marosi, G. Verreck, I. Van Assche,

535 M.E. Brewster, *Inter. J. Pharm.* 486 (2015) 268.

536

537

538

539

540

541

542

543

#### 544 **Captions of Tables and Figures**

545 **Table 1.** Details of the electrospinning processes and the resultant products.

546 **Table 2.** Data on the release of KET from the drug-loaded fibers <sup>a,b</sup> (n=6).

547 **Fig. 1.** The side-by-side electrospinning process: (a) the experimental apparatus (inset: the  
548 connection of the side-by-side spinneret with the working fluids and power supply); (b) a  
549 photograph of a typical side-by-side electrospinning process with the Teflon-coated spinneret;  
550 (c) a Janus Taylor cone formed with the Teflon-coated spinneret; (d) the fiber mat from  
551 side-by-side electrospinning with the uncoated side-by-side spinneret; (e) the separation of  
552 fluids when using the uncoated spinneret; (f) an illustration of the role played by the Teflon  
553 coating: A - the separation of fluids arising from repulsive forces  $F_t$  (between the two Taylor  
554 cones),  $F_s$  (between the two straight fluid jets) and  $F_c$  (between the two coils); and B - the  
555 formation of an integrated Janus Taylor cone with the Teflon coating.

556 **Fig. 2.** FESEM images of the fibers, together with their size distributions: (a) F1 (drug-loaded  
557 PVP fibers); (b) F2 (drug-loaded EC fibers); and the Janus PVP/EC/KET fibers (c) F3; (d) F4;  
558 (e) F5; (f) F6.

559 **Fig. 3.** TEM images of (a) F3; (b) F4; (c) F5; (d) F6.

560 **Fig. 4.** The release of KET from the electrospun nanofibers: (a) the *in vitro* KET release  
561 profiles from the six fibers; (b) the variation of the release percentage and rate in the second  
562 phase as a function of the PVP K10 content in the EC side of the fibers.

563 **Fig. 5.** FESEM images of the fibers remaining after 24h of dissolution and the proposed drug  
564 release mechanism. (a) to (d) show the remains of fibers F3 to F6 respectively; (e) is a  
565 schematic diagram explaining the mechanism of drug release from the Janus fibers.

566